

# Belal Haschimi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8595868/publications.pdf>

Version: 2024-02-01

11  
papers

229  
citations

933447

10  
h-index

1281871

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

204  
citing authors

#	ARTICLE	IF	CITATIONS
1	Development and validation of a rapid LC-MS/MS method for the detection of 182 novel psychoactive substances in whole blood. <i>Drug Testing and Analysis</i> , 2022, 14, 202-223.	2.6	19
2	The Novel Psychoactive Substance Cumyl-CH-MEGACLONE: Human Phase-I Metabolism, Basic Pharmacological Characterization and Comparison to Other Synthetic Cannabinoid Receptor Agonists with a <sup>13</sup> C-Indole-1-One Core. <i>Journal of Analytical Toxicology</i> , 2021, 45, 277-290.	2.8	15
3	Cumyl-CBMICA: A new synthetic cannabinoid receptor agonist containing a cyclobutyl methyl side chain. <i>Drug Testing and Analysis</i> , 2021, 13, 208-216.	2.6	21
4	New synthetic cannabinoids carrying a cyclobutyl methyl side chain: Human Phase I metabolism and data on human cannabinoid receptor 1 binding and activation of Cumyl-CBMICA and Cumyl-CBMINACA. <i>Drug Testing and Analysis</i> , 2021, 13, 1499-1515.	2.6	15
5	Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4-EN-PICA, MDMB-4-EN-PINACA, ADB-4-EN-PINACA, and MMB-4-CN-BUTINACA using a combination of binding and different CB1 receptor activation assays. Part III: The G protein pathway and critical comparison of different assays. <i>Drug Testing and Analysis</i> , 2021, 13, 1412-1429.	2.6	14
6	A transnational perspective on the evolution of the synthetic cannabinoid receptor agonists market: Comparing prison and general populations. <i>Drug Testing and Analysis</i> , 2021, 13, 841-852.	2.6	28
7	Detection and phase I metabolism of the <sup>7</sup> -azaindole-derived synthetic cannabinoid 5F-CAB-7AICA including a preliminary pharmacokinetic evaluation. <i>Drug Testing and Analysis</i> , 2020, 12, 78-91.	2.6	21
8	Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE. <i>Forensic Toxicology</i> , 2020, 38, 314-326.	2.4	21
9	Impact of legislation on NPS markets in Germany – The rise and fall of 5F-CADB. <i>Drug Testing and Analysis</i> , 2020, 12, 853-856.	2.6	21
10	Extraordinary long detection window of a synthetic cannabinoid metabolite in human urine – Potential impact on therapeutic decisions. <i>Drug Testing and Analysis</i> , 2020, 12, 391-396.	2.6	10
11	Detection of the recently emerged synthetic cannabinoid 4F-MDMB-BINACA in “legal high”-products and human urine specimens. <i>Drug Testing and Analysis</i> , 2019, 11, 1377-1386.	2.6	44